Skip to main
CNTA

CNTA Stock Forecast & Price Target

CNTA Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Centessa Pharmaceuticals PLC is positioned favorably due to its robust cash reserves of approximately $405 million, which are projected to sustain operations into mid-2027, allowing for continued development of its promising pipeline. The company's lead asset, ORX750, is anticipated to demonstrate best-in-class efficacy in treating narcolepsy and is supported by positive preliminary outcomes and the potential for enhanced dose-response profiles, which could create substantial differentiation from competitors. Additionally, the estimated sales potential for ORX750 in the narcolepsy market, projected at around $3.6 billion, underscores significant upside potential as the market for orexin agonists expands, fostering optimism among investors.

Bears say

Centessa Pharmaceuticals faces significant commercial and competitive risks due to market pressures from other development assets, which may hinder the potential of its therapeutic offerings. The company is also grappling with high non-responder rates and waning efficacy in key programs, raising concerns about both the effectiveness of its treatments and the potential for optimal dosing strategies. Furthermore, the conservative assessment of market penetration suggests that the stock may be overly optimistic given the challenges outlined, indicating a substantial disconnect between current valuation and future growth prospects.

CNTA has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Centessa Pharmaceuticals PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Centessa Pharmaceuticals PLC (CNTA) Forecast

Analysts have given CNTA a Buy based on their latest research and market trends.

According to 10 analysts, CNTA has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Centessa Pharmaceuticals PLC (CNTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.